Targeted Markets Position the Pu·MA System for contract research organizations and biotech labs focused on oncology, toxicity, and metabolomics, highlighting flowchip-based reagent exchanges as a time-saving, scalable solution for 3D cell models and organoids.

Competitive Differentiator Emphasize patented Valve-less Fluidic Switching VLFS as a unique value proposition that eliminates valves and pumps, offering precision, reduced mechanical complexity, and potential for faster deployment in existing lab workflows.

Growth Synergy Leverage the company’s SF Bay Area presence to pursue collaborations with nearby academic medical centers and biotechs pursuing advanced 3D cell culture, organoids, and personalized medicine programs.

Scale-Ready Offerings Highlight compatibility of Pu·MA System with 3D cell models for oncology and metabolomics research, presenting scalable licensing or service models to mid-sized biotech firms expanding their preclinical pipelines.

Strategic Partnerships Explore channel partnerships with contract research organizations, instrument integrators, and lab automation vendors to broaden reach, supported by targeted content on case studies involving toxicity screening and metabolomics workflows.